Clinical trials: Chronic Pulmonary Obstruction
Chronic Obstructive Pulmonary Disease (COPD)
The Study Will Evaluate the Effect of AZD8683 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to investigate effects of inhaled AZD8683 compared to placebo in COPD patients.
- Trial name
- NCT01205269
- Testing
- AZD8683, 50 mcg, AZD8683, 200 mcg
- Where
- 4 sites in Poland
- Volunteers
- 28 people
- Sponsor
- AstraZeneca
Empyhsema, Pulmonary Disease, Chronic Obstructive
The Spiration Valve System for the Treatment of Severe Emphysema
This is a multicenter, prospective, randomized, controlled study being conducted in China to evaluate improvement of lung function after treatment with the Spiration Valve System as compared to medical management in the control…
- Trial name
- REACH (NCT01989182)
- Testing
- Spiration Valve System, Medical Management
- Where
- 12 sites in China
- Volunteers
- 107 people
- Sponsor
- Olympus Corporation of the Americas
COPD, Pulmonary Disease, Chronic Obstructive
A Long-term Safety Study of Infliximab in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).
The purpose of this long-term observational study is designed to collect additional information on incidence of cancer and cause of death among patients who have participated in clinical trials of infliximab in the treatment of…
- Trial name
- NCT00380796
- Testing
- Collection of safety data for Cohort 1
- Where
- 26 sites in United States
- Volunteers
- 88 people
- Sponsor
- Centocor, Inc.
Chronic Obstructive Pulmonary Disease (COPD)
The Effect of QVA149 on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD)
This study will assess the efficacy and safety of QVA149 compared to tiotropium plus formoterol in patients with moderate to severe COPD.
- Trial name
- QUANTIFY (NCT01574651)
- Testing
- QVA149, Tiotropium, Formoterol
- Where
- 144 sites in Germany
- Volunteers
- 934 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
Comparison of Safety and Efficacy of Berodual® Administered Via the Respimat® Device With That Administered Via the Metered Dose Inhaler (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
To demonstrate that at least one of the two doses of Berodual® (50 µg fenoterol hydrobromide/20 µg ipratropium bromide and 25 µg fenoterol hydrobromide/10 µg ipratropium bromide, 1 puff q.i.d) administered via the Respimat® gives…
- Trial name
- NCT02173782
- Testing
- Berodual® Respimat ® high dose, Berodual® Respimat ® low dose, Berodual® MDI
- Volunteers
- 892 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD)
To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment
This is a Phase 2 study of the efficacy, safety, tolerability and pharmacokinetics of two doses of EXPD-101 in participants with COPD.
- Trial name
- Navigator (NCT07684820)
- Testing
- EXPD-101/FXS7553 Dose 1, EXPD-101/FXS7553 Dose 2
- Where
- 35 sites in United States, Canada and 2 more
- Volunteers
- 600 people
- Sponsor
- Expedition Therapeutics, Inc
Pulmonary Disease, Chronic Obstructive
Preference Attributes of ELLIPTA Dry Powder Inhaler (DPI) and HANDIHALER DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
This is a Phase IV multi-center, randomized, open-label, cross-over, placebo study in subjects with Chronic Obstructive Pulmonary Disease (COPD) to compare inhaler-specific preference attributes of two inhalers - ELLIPTA dry…
- Trial name
- NCT02786927
- Testing
- Inhaler Preference Questionnaire Version 1, Inhaler Preference Questionnaire Version 2
- Where
- 22 sites in United States
- Volunteers
- 214 people
- Sponsor
- GlaxoSmithKline
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
This open-label study will evaluate the safety of continued therapy with inhaled treprostinil in participants who have completed Study RIN-PH-304 (NCT03496623).
- Trial name
- PERFECT OLE (NCT03794583)
- Testing
- Inhaled treprostinil solution
- Where
- 32 sites in United States, Israel and 1 more
- Volunteers
- 41 people
- Sponsor
- United Therapeutics
Pulmonary Disease, Chronic Obstructive
Free Combinations of Tiotropium Inhalation Powder Capsule + Salmeterol Metered Dose Inhaler, Tiotropium Inhalation Powder Capsule and Salmeterol Metered Dose Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Main Study: To evaluate and to compare the lung function response to the free combinations of tiotropium 18 μg (QD) + salmeterol 50 μg (QD or BID), salmeterol 50 μg BID and tiotropium 18 μg QD at the end of 6-week treatment…
- Trial name
- NCT02242253
- Testing
- Tiotropium, Salmeterol
- Volunteers
- 97 people
- Sponsor
- Boehringer Ingelheim
Advanced Upper Lobe Predominant Emphysema
Phase 3 Study of the Biologic Lung Volume Reduction (BLVR) System in Advanced Upper Lobe Predominant (ULP) Emphysema
The purpose of the study is to evaluate the efficacy and safety of the 20 mL BLVR System in treating patients with advanced upper lobe predominant emphysema.
- Trial name
- NCT00716053
- Testing
- BLVR
- Volunteers
- 225 people
- Sponsor
- Aeris Therapeutics
Copd
Assessment of Bronchodilator Efficacy of Formoterol/Budesonide 12/400 mcg Via Discair in COPD
The overall objective is to asses the bronchodilator effect of single dose of Formoterol/Budesonide 12/400 mcg fixed combination delivered via Discair® in patients with COPD.
- Trial name
- COPD (NCT03028701)
- Testing
- Formoterol/Budesonide 12/400 mcg Discair
- Where
- Turkey (Türkiye)
- Volunteers
- 33 people
- Sponsor
- Neutec Ar-Ge San ve Tic A.Ş
COPD
A Six Month Randomized Controlled Clinical Trial of Lung Flute in Patients With Chronic Obstructive Pulmonary Disease
This is a 26 week randomized controlled study. The study consists of, in order, an enrollment visit, followed by clinic visits at 2 weeks, 14 weeks and at 26 weeks.
- Trial name
- NCT01186822
- Testing
- Lung Flute
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Nicolaas J Smit PhD
COPD
Study to Determine the Amount of Glycopyrrolate Absorbed in the Lungs After Taking the Medicine With a eFlow Nebulizer and Seebri® Breezhaler® With and Without Activated Charcoal in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).
The purpose of this research study is to determine the amount of medicine absorbed in the lungs following dosing via eFlow nebulizer and Seebri® Breezhaler® with and without activated charcoal in subjects with moderate to severe…
- Trial name
- GOLDEN7 (NCT02512302)
- Testing
- SUN-101 via eFlow nebulizer, SUN-101 via eFlow nebulizer with activated charcoal, Seebri® Breezhaler®
- Where
- 2 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Sunovion Respiratory Development Inc.
Chronic Obstructive Pulmonary Disease, COPD
A Single-dose Study to Investigate the Effects of 4 Different Doses of Inhaled AZD8683 in Chronic Obstructive Pulmonary Disease (COPD) Patients
This study in Chronic Obstructive Pulmonary Disease (COPD) patients will investigate the bronchodilatory effect of AZD8683. AZD8683 will be tested versus placebo and an active comparator.
- Trial name
- NCT01708057
- Testing
- AZD8683, Tiotropium
- Where
- 6 sites in Poland, Sweden
- Volunteers
- 3 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
PT001 MDI Versus Atrovent Study in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
The overall objective of this study is to determine an optimal dose and dosing regimen of PT001 MDI for further evaluation in later stage studies.
- Trial name
- NCT01350128
- Testing
- PT001 MDI, Ipratropium Bromide HFA Inhalation Aerosol
- Where
- 8 sites in United States
- Volunteers
- 103 people
- Sponsor
- Pearl Therapeutics, Inc.
COPD, Particulate Matter Induced Inflammation of the Lung
Efficacy and Feasibility of Ectoin® Inhalation Solution in Inflammatory Obstruction and Ageing of the Lung
To investigate the physical inflammation inhibition effects of EIL (Ectoin-Hydro-Complex) in subjects of the established SALIA-cohort and the preventive effects on lung function decline.
- Trial name
- EFECT (NCT01225965)
- Testing
- Ectoin Inhalation Solution
- Where
- Germany
- Volunteers
- 36 people
- Sponsor
- Bitop AG
Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Study to Evaluate the Clinical Value and Safety of Xiyanping Injection in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease(COPD) Based on Real-world Clinical Data
The primary objective is to evaluate the effect of Xiyanping injection on the treatment course of intravenous antibiotics for acute exacerbation of chronic obstructive pulmonary disease based on real-world clinical data, and to…
- Trial name
- XYP-202401 (NCT06754865)
- Testing
- Xiyanping injection+ antibiotic, Antibiotic
- Volunteers
- 1,140 people
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Pulmonary Disease, Chronic Obstructive
Effects of a 9-months Treatment of SPIRIVA on Health Related Quality of Life in Patients With COPD
The purpose of this study is to investigate the effect of a 9-month treatment of tiotropium (SPIRIVA®) 18 mcg once daily on Health Related Quality of Life and lung function in patients with a Chronic Obstructive Pulmonary Disease.
- Trial name
- NCT00274053
- Testing
- tiotropium
- Where
- 27 sites in France
- Volunteers
- 555 people
- Sponsor
- Boehringer Ingelheim
Cystic Fibrosis (CF), Non Cystic Fibrosis Bronchiectasis
Feasibility and Acceptance of SonoHeal for Airway Clearance and Preliminary Comparison With the Standard of Care
The proposed study is to gauge the early feasibility and acceptance of the SonoHeal device. The study will evaluate the usability of the SonoHeal prototype using well-established Human Factors Engineering methods recommended by…
- Conditions
- Cystic Fibrosis (CF), Non Cystic Fibrosis Bronchiectasis, Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT07568119
- Testing
- Airway clearance therapy through acoustic oscillations
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Cognita Labs LLC
Pulmonary Disease, Chronic Obstructive
Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in Chronic Obstructive Pulmonary Disease (COPD)
Comparison of lung function response between tiotropium inhalation solution and Spiriva HandiHaler.
- Trial name
- NCT00281567
- Testing
- Tiotropium, Respimat SMI, HandiHaler
- Where
- 2 sites in Belgium, Netherlands
- Volunteers
- 76 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.